Literature DB >> 19230025

Overexpression of Aurora A by loss of CHFR gene expression increases the growth and survival of HTLV-1-infected T cells through enhanced NF-kappaB activity.

Mariko Tomita1, Minoru Toyota, Chie Ishikawa, Tetsuro Nakazato, Taeko Okudaira, Takehiro Matsuda, Jun-Nosuke Uchihara, Naoya Taira, Kazuiku Ohshiro, Masachika Senba, Yuetsu Tanaka, Koichi Ohshima, Hideyuki Saya, Takashi Tokino, Naoki Mori.   

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent for adult T-cell leukemia (ATL). Aurora A, a mitotic checkpoint protein, is overexpressed in human cancer cells. The cell cycle-dependent turnover of Aurora A is regulated by E3 ubiquitin ligases such as checkpoint with fork head-associated and ring finger (CHFR). Here, we found overexpression of Aurora A protein in HTLV-1-infected T-cell lines and primary ATL cells. The expression of CHFR mRNA was reduced in these cells by abnormal methylation of CHFR promoter region. Knockdown of Aurora A using small interfering RNA suppressed the growth of HTLV-1-infected T-cell line. Transfection of Aurora A expression plasmid enhanced Tax-induced nuclear factor-kappaB (NF-kappaB) reporter activity. Transfection of CHFR expression plasmid into an HTLV-1-infected T-cell line reduced cell growth, Aurora A protein level and constitutive NF-kappaB reporter activity. Aurora kinase inhibitor suppressed the growth and survival of HTLV-1-infected T-cell lines and primary ATL cells. It also reduced constitutive NF-kappaB activity in an HTLV-1-infected T-cell line by reducing IkappaB kinase beta phosphorylation and the expression of antiapoptotic protein survivin. Our results suggested that loss of CHFR expression resulted to accumulation of Aurora A, which increased NF-kappaB activity. These findings highlight the critical role of Aurora A in HTLV-1-infected T cells, making this molecule a potentially suitable target for future therapies for ATL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19230025     DOI: 10.1002/ijc.24257

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas.

Authors:  Norman L Lehman; James P O'Donnell; Lisa J Whiteley; Robert T Stapp; Trang D Lehman; Kathleen M Roszka; Lonni R Schultz; Caitlin J Williams; Tom Mikkelsen; Stephen L Brown; Jeffrey A Ecsedy; Laila M Poisson
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

Review 2.  Safeguarding entry into mitosis: the antephase checkpoint.

Authors:  Cheen Fei Chin; Foong May Yeong
Journal:  Mol Cell Biol       Date:  2010-01       Impact factor: 4.272

Review 3.  Human T-lymphotropic virus proteins and post-translational modification pathways.

Authors:  Carlo Bidoia
Journal:  World J Virol       Date:  2012-08-12

4.  Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.

Authors:  Karthik Venkatakrishnan; Tae Min Kim; Chia-Chi Lin; Lim Soon Thye; Wee Joo Chng; Brigette Ma; Ming Huang Chen; Xiaofei Zhou; Hua Liu; Virginia Kelly; Won Seog Kim
Journal:  Invest New Drugs       Date:  2015-06-19       Impact factor: 3.850

5.  Quantitative proteome analysis of pluripotent cells by iTRAQ mass tagging reveals post-transcriptional regulation of proteins required for ES cell self-renewal.

Authors:  Robert N O'Brien; Zhouxin Shen; Kiyoshi Tachikawa; Pei Angel Lee; Steven P Briggs
Journal:  Mol Cell Proteomics       Date:  2010-05-31       Impact factor: 5.911

6.  Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Authors:  Jonathan W Friedberg; Daruka Mahadevan; Erin Cebula; Daniel Persky; Izidore Lossos; Amit B Agarwal; Jungah Jung; Richard Burack; Xiaofei Zhou; E Jane Leonard; Howard Fingert; Hadi Danaee; Steven H Bernstein
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

7.  Kaposi's sarcoma herpesvirus upregulates Aurora A expression to promote p53 phosphorylation and ubiquitylation.

Authors:  Qiliang Cai; Bingyi Xiao; Huaxin Si; Amanda Cervini; Jianming Gao; Jie Lu; Santosh K Upadhyay; Suhbash C Verma; Erle S Robertson
Journal:  PLoS Pathog       Date:  2012-03-01       Impact factor: 6.823

8.  Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  Kevin R Kelly; Thomas C Shea; André Goy; Jesus G Berdeja; Craig B Reeder; Kevin T McDonagh; Xiaofei Zhou; Hadi Danaee; Hua Liu; Jeffrey A Ecsedy; Huifeng Niu; Ely Benaim; Swaminathan Padmanabhan Iyer
Journal:  Invest New Drugs       Date:  2013-12-20       Impact factor: 3.850

9.  Silencing of HTLV-1 gag and env genes by small interfering RNAs in HEK 293 cells.

Authors:  Rodrigo Haddad; Simone Kashima; Evandra Strazza Rodrigues; Rochele Azevedo; Patrícia Vianna Bonini Palma; Danielle Aparecida Rosa de Magalhães; Marco Antonio Zago; Dimas Tadeu Covas
Journal:  J Virol Methods       Date:  2011-01-26       Impact factor: 2.014

Review 10.  Biomarker-driven management strategies for peripheral T cell lymphoma.

Authors:  Erin Mulvey; Jia Ruan
Journal:  J Hematol Oncol       Date:  2020-05-24       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.